HER2-TARGETED THERAPIES

In a database review of patients diagnosed with advanced HER2-positive breast cancer in Australia, researchers reported that anti-HER2 therapy–related cardiotoxicity is an uncommon complication in the real-world setting. They also noted that cardiac toxicity resolved in the majority of affected patients, and that patients were able to receive further anti‐HER2 therapy without recurrence of the cardiac issues.